K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · EW
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | EW | EDWARDS LIFESCIENCES LLC | EDWARDS LIFESCIENCES, LLC | $340K | Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Transitional Coverage for Emerging Technologies (TCET)/MCIT Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization/FDA User Fees Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development CMS Coverage Policies For Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.5343/S.1717) (includes MCIT/TCET) Heart Valve Disease Awareness Transcatheter Mitral Valve National Coverage Decision National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials (Health Equity Issues) Coverage with Evidence Development Tariffs |
| 2026-04-20 | EW | EDWARDS LIFESCIENCES LLC | FARRAGUT PARTNERS LLP | $50K | Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0 |
| 2026-04-20 | EW | EDWARDS LIFESCIENCES LLC | BGR GOVERNMENT AFFAIRS | $50K | Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue |
| 2026-04-20 | EW | EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | $50K | Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders; Issues related to Senate Finance Dear Colleague process |
| 2026-01-20 | EW | EDWARDS LIFESCIENCES LLC | EDWARDS LIFESCIENCES, LLC | $350K | Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development Japan Reimbursement of Medical Devices |
| 2026-01-20 | EW | EDWARDS LIFESCIENCES LLC | BGR GOVERNMENT AFFAIRS | $50K | Provide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issue |
| 2026-01-20 | EW | EDWARDS LIFESCIENCES LLC | FARRAGUT PARTNERS LLP | $50K | Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0 |
| 2026-01-20 | EW | EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | $50K | Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders |
| 2025-10-20 | EW | EDWARDS LIFESCIENCES LLC | EDWARDS LIFESCIENCES, LLC | $280K | Corporate Tax Reform Proposals Tariffs Japan Reimbursement of Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization/FDA User Fees Diversity in Clinical Trials CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R. 5343/S.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development |
| 2025-10-20 | EW | EDWARDS LIFESCIENCES LLC | FARRAGUT PARTNERS LLP | $50K | Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0 |
| 2025-10-20 | EW | EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | $50K | Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 5343/S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Expiring healthcare extenders |
| 2025-07-21 | EW | EDWARDS LIFESCIENCES LLC | FARRAGUT PARTNERS LLP | $50K | Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0 |
| 2025-07-21 | EW | EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | $50K | Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); S. 1717, Ensuring Patient Access to Critical Breakthrough Products Act of 2025; Health care issues in H.R. 1, To provide for reconciliation pursuant to title II of H. Con. Res. 14. (Public Law No: 119-21) |
| 2025-07-18 | EW | EDWARDS LIFESCIENCES LLC | EDWARDS LIFESCIENCES, LLC | $360K | Ensuring Patient Access to Critical Breakthrough Products (S.1717) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness AI in Healthcare FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (s.1717) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development Corporate Tax Reform Proposals Tariffs |
| 2025-04-21 | EW | EDWARDS LIFESCIENCES LLC | FARRAGUT PARTNERS LLP | $50K | Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0 |
| 2025-04-21 | EW | EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | $50K | Issues related to the CMS Rule: Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4); Medicare coverage of breakthrough technologies |
| 2025-04-18 | EW | EDWARDS LIFESCIENCES LLC | EDWARDS LIFESCIENCES, LLC | $350K | Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development Corporate Tax Reform Proposals Tariffs Veterans Access to MedTech |
| 2025-01-21 | EW | EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | $70K | Issues related to the CMS Rule: Medicare Coverage of Innovative Technology; Issues related to Transitional Coverage for Emerging Technologies (TCET) (CMS-3421); H.R. 8816, American Medical Innovation and Investment Act of 2024; H.R. 10545, American Relief Act, 2025 |
| 2025-01-21 | EW | EDWARDS LIFESCIENCES LLC | FARRAGUT PARTNERS LLP | $50K | Coverage and reimbursement policy for medical devices/THV Medicare coverage of breakthrough therapies Policies promoting medical innovation. Coverage with evidence development. 21st Century Cures 2.0 |